In this study, biopolymer composites based on chitosan (CS) with enhanced optical properties were functionalized using Manganese metal complexes and black tea solution dyes. The results indicate that CS with Mn-complexes can produce polymer hybrids with high absorption, high refractive index and controlled optical band gaps, with a significant reduction from 6.24 eV to 1.
View Article and Find Full Text PDFThe current research aims to determine the impact of orange peel dye (OPD), an eco-friendly addition, on the optical properties of biodegradable polymers. This study investigates the enhancement of optical properties in solid electrolytes based on chitosan (CS) and glycerol, with varying OPD concentrations. UV-Vis-NIR spectroscopy revealed significantly enhanced UV-visible light absorption in the 200-500 nm region and effective UV light blocking.
View Article and Find Full Text PDFThe current study used sustainable and green approaches to convey polymer composites with desired optical properties. The extracted green tea dye (GTD) enriched with ligands was used to synthesize zinc metal complexes. Green chitosan biopolymer incorporated with green synthesized metal complex using casting technique was used to deliver polymer composites with improved optical properties.
View Article and Find Full Text PDFBackground: The advances in technology have enabled the customization of appliances including mini-screw-assisted rapid palatal expansion (MARPE) appliances for skeletal expansion in young adult patients. The study assessed the short-term effects of customized MARPE appliances on the hard tissues, soft tissues, and airway volume over a period of 6 months.
Methods: A total of 15 patients in the age range of 15 to 25 years were treated for transverse maxillary deficiency using a three-dimensional (3D) printed customized MARPE appliance.
Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.
Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.